ANX007

DRUG3 trials

Sponsors

Annexon Inc., Annexon, Inc.

Conditions

Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA)Geographic AtrophyOpen-angle Glaucoma

Phase 1

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

CompletedNCT03488550

Annexon, Inc.Open-angle Glaucoma

Start: 2018-03-23End: 2018-08-03Updated: 2020-08-20

Phase 2

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

CompletedNCT04656561

Annexon, Inc.Geographic Atrophy

Start: 2021-02-26End: 2023-09-13Updated: 2024-08-21

Phase 3

A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Participants with Dry Age-Related Macular Degeneration with Geographic Atrophy

Active, not recruitingCTIS2024-515022-88-00

Annexon Inc.Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA)

Start: 2025-03-03Target: 125Updated: 2025-10-15